Comparative Pharmacology
Head-to-head clinical analysis: PROTAMINE SULFATE versus PROVAYBLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTAMINE SULFATE versus PROVAYBLUE.
PROTAMINE SULFATE vs PROVAYBLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Protamine sulfate is a cationic protein that binds to heparin, an anionic anticoagulant, forming a stable complex that neutralizes heparin's anticoagulant activity. It also has mild anticoagulant properties of its own.
Methylthioninium chloride (methylene blue) acts by reducing methemoglobin to hemoglobin via the enzyme NADPH methemoglobin reductase, thereby restoring oxygen-carrying capacity of the blood.
1 mg IV per 100 units of heparin to be neutralized, administered slowly (not exceeding 5 mg/min) with continuous monitoring. Maximum single dose: 50 mg.
1-2 mg/kg intravenously over 5 minutes, may repeat once if needed. Maximum single dose: 300 mg.
None Documented
None Documented
Complex with heparin: 4–5 minutes (free protamine: 7.4 minutes). Clinically, the anticoagulant reversal effect is rapid but may be transient due to heparin rebound.
Terminal elimination half-life is approximately 10-15 hours. In patients with renal impairment, half-life may be prolonged; no dose adjustment recommended for mild-to-moderate impairment, but use caution in severe impairment.
Primarily renal excretion (heparin-protamine complexes are cleared by the reticuloendothelial system; elimination is largely independent of renal function). <5% excreted unchanged in urine.
Primarily renal excretion as unchanged drug. Approximately 45-60% of a dose is excreted unchanged in urine. Minor fecal elimination accounts for less than 10%.
Category A/B
Category C
Antidote
Antidote